Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Harvard Business School
Accenture
US Army
Dow
AstraZeneca
UBS
Daiichi Sankyo
US Department of Justice
Julphar

Generated: January 17, 2018

DrugPatentWatch Database Preview

ALLI Drug Profile

« Back to Dashboard

When do Alli patents expire, and when can generic versions of Alli launch?

Alli is a drug marketed by Glaxosmithkline Cons and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has forty patent family members in thirty-three countries.

The generic ingredient in ALLI is orlistat. There are eleven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the orlistat profile page.
Summary for ALLI
Drug patent expirations by year for ALLI

US Patents and Regulatory Information for ALLI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons ALLI orlistat CAPSULE;ORAL 021887-001 Feb 7, 2007 OTC Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ALLI
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules 60 mg ➤ Subscribe 9/8/2010

International Patents for ALLI

Supplementary Protection Certificates for ALLI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/044 United Kingdom ➤ Subscribe PRODUCT NAME: ORLISTAT; REGISTERED: UK EU/1/98/071/001 19980729; UK EU/1/98/071/002 19980729; UK EU/1/98/071/003 19980729; UK EO/1/98/071/004 19980729; UK EU/1/98/071/005 19980729; UK EU/1/98/071/006 19980729
C0042 Belgium ➤ Subscribe PRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Moodys
Argus Health
Fish and Richardson
Julphar
Merck
Harvard Business School
Cerilliant
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot